Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Dr. Nowakowski on the Rationale of the ENGINE Trial in DLBCL

September 22nd 2020

Grzegorz S. Nowakowski, MD, discusses the rationale for the ongoing, randomized phase 3 ENGINE study in diffuse large B-cell lymphoma.

Dr. Hill on the SADAL Trial With Selinexor in DLBCL

September 22nd 2020

Brian T. Hill, MD, PhD, discusses the data from the SADAL trial that led to the FDA approval of selinexor for use in patients with diffuse large B-cell lymphoma.

Dr. Maddocks on Remaining Challenges in Follicular Lymphoma

September 22nd 2020

Kami J. Maddocks, MD, discusses remaining challenges in treating patients with follicular lymphoma.

Dr. Skarbnik on the Importance of Personalized Treatment for Follicular Lymphoma

September 19th 2020

Alan P. Z. Skarbnik, MD, discusses the importance of personalizing treatment for patients with follicular lymphoma.

Dr. Batlevi on Challenges Faced in Follicular Lymphoma Management

September 18th 2020

Connie L. Batlevi, MD, PhD, discusses challenges faced in the treatment of patients with follicular lymphoma.

Dr. Balzarotti on the Challenges of Treating Elderly DLBCL

September 18th 2020

Monica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.

Dr. Deol on the Approval of Brexucabtagene Autoleucel in MCL

September 17th 2020

Abhinav Deol, MD, discusses the approval of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma.

Dr. Bachier on the Potential Benefits of Liso-Cel in DLBCL

September 17th 2020

Carlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.

Dr. Kahl on Remaining Challenges in Indolent Non-Hodgkin Lymphoma

September 17th 2020

Brad S. Kahl, MD, discusses remaining challenges in the indolent non-Hodgkin lymphoma treatment landscape.

Dr. Maddocks on Unanswered Questions With BTK Inhibitors in B-Cell Malignancies

September 16th 2020

Kami J. Maddocks, MD, discusses unanswered questions with BTK inhibitors in B-cell malignancies.

Dr. Burke on Treatment Options in Low-Tumor Burden Follicular Lymphoma

September 16th 2020

John M. Burke, MD, discusses treatment options for patients with early-stage or advanced follicular lymphoma with a low tumor burden.

Dr. Pagel on the Evolution of Treatment in DLBCL

September 16th 2020

John M. Pagel, MD, PhD, discusses the evolution of treatment in diffuse large B-cell lymphoma.

Dr. Kahl on the Current Treatment Landscape in Relapsed/Refractory iNHL

September 15th 2020

Brad S. Kahl, MD, discusses the current treatment landscape in relapsed/refractory indolent non-Hodgkin lymphoma.

Relapsed/Refractory DLBCL Paradigm Gains Chemotherapy-Free Option

September 15th 2020

Kami J. Maddocks, MD, discusses the tolerability and promise of tafasitamab in combination with lenalidomide in relapsed or refractory DLBCL.

Dr. Maddocks on the Role of Tazemetostat in EZH2-Mutant Follicular Lymphoma

September 14th 2020

Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.

BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness

September 11th 2020

Shuo Ma, MD, PhD, discusses the evolving role of BTK inhibitors in B-cell malignancies, ongoing research efforts examining their use, safety concerns to be aware of with the agents, and next steps for research.

Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies

September 11th 2020

Lori A. Leslie, MD, highlights ibrutinib, acalabrutinib, and zanubrutinib, the 3 FDA approved BTK inhibitors that have become very important weapons in the treatment arsenal for B-cell malignancies.

Ibrutinib Plus Rituximab Approved in Europe for Frontline CLL

September 10th 2020

The European Commission has approved an expanded indication of ibrutinib for use in combination with rituximab in treatment-naïve adult patients with chronic lymphocytic leukemia.

Balzarotti Breaks Down New Developments in the Expanding DLBCL Paradigm

September 9th 2020

Monica Balzarotti, MD, discusses the current treatment landscape of DLBCL, including the recent FDA approval of selinexor for the treatment of adult patients with relapsed/refractory disease.

Brody Calls for Effective Predictive Biomarker of Response to Selinexor in DLBCL

September 7th 2020

Joshua Brody, MD, discusses recent developments in DLBCL treatment, the role of selinexor, and the need for effective biomarkers of response in the space.